Management of Psychotic Illnesses in Primary Care Settings

References (66)

1. Byng R. Recognizing and managing psychosis in primary care. Psychiatry. 2008;7(11):477–481. CrossRef
2. Anderson KK, Fuhrer R, Wynant W, et al. Patterns of health services use prior to a first diagnosis of psychosis: the importance of primary care. Soc Psychiatry Psychiatr Epidemiol. 2013;48(9):1389–1398. PubMed CrossRef
3. Tandon N, Shah J, Keshavan MS, et al. Attenuated psychosis and the schizophrenia prodrome: current status of risk identification and psychosis prevention. Neuropsychiatry. 2012;2(4):345–353. PubMed CrossRef
4. Chen Y, Farooq S, Edwards J, et al. Patterns of symptoms before a diagnosis of first episode psychosis: a latent class analysis of UK primary care electronic health records. BMC Med. 2019;17(1):227. PubMed CrossRef
5. Larson MK, Walker EF, Compton MT. Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders. Expert Rev Neurother. 2010;10(8):1347–1359. PubMed CrossRef
6. Newman-Taylor K, Maguire T, Smart T, et al. Screening for psychosis risk in primary mental health care services – implementation, prevalence and recovery trajectories. Br J Clin Psychol. 2024;63(4):589–602. PubMed CrossRef
7. Olfson M, Lewis-Fernández R, Weissman MM, et al. Psychotic symptoms in an urban general medicine practice. Am J Psychiatry. 2002;159(8):1412–1419. PubMed CrossRef
8. Perälä J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64(1):19–28. PubMed CrossRef
9. Moreno-Küstner B, Martín C, Pastor L. Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. PloS One. 2018;13(4):e0195687. PubMed CrossRef
10. Oud MJT, Schuling J, Groenier KH, et al. Care provided by general practitioners to patients with psychotic disorders: a cohort study. BMC Fam Pract. 2010;11:92. PubMed CrossRef
11. Wiener JC, Rodrigues R, Reid JNS, et al. Patient and physician factors associated with first diagnosis of non-affective psychotic disorder in primary care. Adm Policy Ment Health. 2023;50(2):212–224. PubMed CrossRef
12. Savill M, Loewy RL, Niendam TA, et al. The diagnostic accuracy of screening for psychosis spectrum disorders in behavioral health clinics integrated into primary care. Schizophr Res. 2024;266:190–196. PubMed CrossRef
13. Goldbloom DS, Davine J. Psychiatry in Primary Care: A Concise Canadian Pocket Guide. Centre for Addiction and Mental Health; 2019.
14. Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29(4):703–715. PubMed CrossRef
15. French P, Owens J, Parker S, et al. Identification of young people in the early stages of psychosis: validation of a checklist for use in primary care. Psychiatry Res. 2012;200(2-3):911–916. PubMed CrossRef
16. Loewy RL, Pearson R, Vinogradov S, et al. Psychosis risk screening with the prodromal Questionnaire — brief version (PQ-B). Schizophr Res. 2011;129(1):42–46. PubMed CrossRef
17. Phalen PL, Rouhakhtar PR, Millman ZB, et al. Validity of a two-item screen for early psychosis. Psychiatry Res. 2018;270:861–868. PubMed CrossRef
18. Post RM. The status of the sensitization/kindling hypothesis of bipolar disorder. Curr Psychos Ther Rep. 2004;2(4):135–141. CrossRef
19. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006;3(2):A42. PubMed
20. Ringen PA, Engh JA, Birkenaes AB, et al. Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions. Front Psychiatry. 2014;5:137. PubMed CrossRef
21. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123–1131. PubMed CrossRef
22. De Hert M, McKenzie K, Peuskens J. Risk factors for suicide in young people suffering from schizophrenia: a long-term follow-up study. Schizophr Res. 2001;47(2–3):127–134. PubMed CrossRef
23. Brown S, Mitchell C. Predictors of death from natural causes in schizophrenia: 10- year follow-up of a community cohort. Soc Psychiatry Psychiatr Epidemiol. 2012;47(6):843–847. PubMed CrossRef
24. Schultz SH, North SW, Shields CG. Schizophrenia: a review. Am Fam Physician. 2007;75(12):1821–1829. PubMed
25. Docherty M, Stubbs B, Gaughran F. Strategies to deal with comorbid physical illness in psychosis. Epidemiol Psychiatr Sci. 2016;25(3):197–204. PubMed CrossRef
26. Dickerson F, Stallings C, Origoni A, et al. Mortality in schizophrenia: clinical and serological predictors. Schizophr Bull. 2014;40(4):796–803. PubMed CrossRef
27. Kelly DL, McMahon RP, Wehring HJ, et al. Cigarette smoking and mortality risk in people with schizophrenia. Schizophr Bull. 2011;37(4):832–838. PubMed CrossRef
28. Kumari V, Postma P. Nicotine use in schizophrenia: the self medication hypotheses. Neurosci Biobehav Rev. 2005;29(6):1021–1034. PubMed CrossRef
29. Masterson E, O’Shea B. Smoking and malignancy in schizophrenia. Br J Psychiatry. 1984;145:429–432. PubMed CrossRef
30. Kelly C, McCreadie RG. Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry. 1999;156(11):1751–1757. PubMed CrossRef
31. Domino EF, Mirzoyan D, Tsukada H. N-methyl-D-aspartate antagonists as drug models of schizophrenia: a surprising link to tobacco smoking. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(5):801–811. PubMed CrossRef
32. Goff DC, Cather C, Evins AE, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005;66(2):183–274. PubMed CrossRef
33. Hughes E, Bassi S, Gilbody S, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis. Lancet Psychiatry. 2016;3(1):40–48. PubMed CrossRef
34. Lluch E, Miller BJ. Rates of hepatitis B and C in patients with schizophrenia: a meta-analysis. Gen Hosp Psychiatry. 2019;61:41–46. PubMed CrossRef
35. Suvisaari J, Keinänen J, Eskelinen S, et al. Diabetes and schizophrenia. Curr Diab Rep. 2016;16(2):16. PubMed CrossRef
36. Miller BJ, Paschall CB, Svendsen DP. Mortality and medical comorbidity among patients with serious mental illness. Psychiatr Serv. 2006;57(10):1482–1487. PubMed CrossRef
37. Crump C, Winkleby MA, Sundquist K, et al. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry. 2013;170(3):324–333. PubMed CrossRef
38. Leucht S, Burkard T, Henderson J, et al. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand. 2007;116(5):317–333. PubMed CrossRef
39. Zhuo C, Tao R, Jiang R, et al. Cancer mortality in patients with schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2017;211(1):7–13. PubMed CrossRef
40. Nordentoft M, Plana-Ripoll O, Laursen TM. Cancer and schizophrenia. Curr Opin Psychiatry. 2021;34(3):260–265. PubMed CrossRef
41. Zhou K, Zhu L, Chen N, et al. Causal associations between schizophrenia and cancers risk: a Mendelian randomization study. Front Oncol. 2023;13:1258015. PubMed CrossRef
42. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150(6):1115–1121. PubMed CrossRef
43. Nielsen J, Juel J, Alzuhairi KS, et al. Unrecognised myocardial infarction in patients with schizophrenia. Acta Neuropsychiatr. 2015;27(2):106–112. PubMed CrossRef
44. Bodén R, Molin E, Jernberg T, et al. Higher mortality after myocardial infarction in patients with severe mental illness: a nationwide cohort study. J Intern Med. 2015;277(6):727–736. PubMed CrossRef
45. Hauck TS, Liu N, Wijeysundera HC, et al. Mortality and revascularization among myocardial infarction patients with schizophrenia: a population-based cohort study. Can J Psychiatry. 2020;65(7):454–462. PubMed CrossRef
46. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med. 1998;338(21):1516–1520. PubMed CrossRef
47. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17(2):325–351. PubMed CrossRef
48. Pantelis C, Barnes TRE. Drug strategies and treatment-resistant schizophrenia. Aust N Z J Psychiatry. 1996;30(1):20–37. PubMed CrossRef
49. Perkins DO. Adherence to antipsychotic medications. J Clin Psychiatry. 1999;60(suppl 21):25–30. PubMed
50. Zipursky RB, Menezes NM, Streiner DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res. 2014;152(2–3):408–414. PubMed CrossRef
51. Kane JM, Malhotra A. The future of pharmacotherapy for schizophrenia. World Psychiatry. 2003;2(2):81–86. PubMed
52. Olfson M, Mechanic D, Hansell S, et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv. 2000;51(2):216–222. PubMed CrossRef
53. Francey SM, Nelson B, Thompson A, et al. Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. Schizophr Res. 2010;119(1–3):1–10. PubMed CrossRef
54. Thomas KC, Ellis AR, Konrad TR, et al. County-level estimates of mental health professional shortage in the United States. Psychiatr Serv. 2009;60(10):1323–1328. PubMed CrossRef
55. Howland M, Chang D, Ratzliff A, et al. C-L case conference: chronic psychosis managed in collaborative care. J Acad Consult Liaison Psychiatry. 2022;63(3):189–197. PubMed CrossRef
56. Grove LR, Olesiuk WJ, Ellis AR, et al. Evaluating the potential for primary care to serve as a mental health home for people with schizophrenia. Gen Hosp Psychiatry. 2017;47:14–19. PubMed CrossRef
57. Miller AL, Crismon ML, Rush AJ, et al. The Texas Medication Algorithm Project: clinical results for schizophrenia. Schizophr Bull. 2004;30(3):627–647. PubMed CrossRef
58. Lenior ME, Dingemans PMAJ, Linszen DH, et al. Social functioning and the course of early-onset schizophrenia: five-year follow-up of a psychosocial intervention. Br J Psychiatry. 2001;179(1):53–58. PubMed CrossRef
59. Camacho-Gomez M, Castellvi P. Effectiveness of family intervention for preventing relapse in first-episode psychosis until 24 Months of follow-up: a systematic review with meta-analysis of randomized controlled trials. Schizophr Bull. 2020;46(1):98–109. PubMed CrossRef
60. Wang PS, Lane M, Olfson M, et al. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):629–640. PubMed CrossRef
61. Testa M, West SG. Civil commitment in the United States. Psychiatry. 2010;7(10):30–40. PubMed
62. Freudenreich O, Stern TA. Clinical experience with the management of schizophrenia in the general hospital. Psychosomatics. 2003;44(1):12–23. PubMed CrossRef
63. Viron MJ, Stern TA. The impact of serious mental illness on health and healthcare. Psychosomatics. 2010;51(6):458–465. PubMed CrossRef
64. Vyas CM, Petriceks AH, Paudel S, et al. Acute psychosis: differential diagnosis, evaluation, and management. Prim Care Companion CNS Disord. 2023;25(2):22f03338–w10. PubMed CrossRef
65. Johnson JM, Stern TA. Involuntary hospitalization of primary care patients. Prim Care Companion CNS Disord. 2014;16(3):PCC.13f01613. doi:10.4088/PCC. 13f01613. PubMed CrossRef
66. Freudenreich O, Cather C, Stern TA. Facing Serious Mental Illness: A Guide for Patients and their Families. Massachusetts General Hospital Psychiatry Academy; 2021.